10-K: Cavitation Technologies Faces Financial Strain Amidst Tender Offer

Cavitation Technologies reports a drastic revenue drop to $3,000 for fiscal year 2026, a net loss of $1.4 million, and substantial doubt about its ability to continue as a going concern, though a $35 million tender offer is pending.

Summary

• Cavitation Technologies, Inc. reported a significant decline in revenue for the fiscal year ended June 30, 2026, with total revenue of $3,000, a decrease of 98.5% from $203,000 in the prior year.
• The company incurred a net loss of $1,404,000 for fiscal year 2026, a substantial increase from a net loss of $113,000 in fiscal year 2025.
• General and administrative expenses increased by 30.6% to $1,380,000, largely due to stock-based compensation and consulting fees.
• Research and development expenses decreased by 88.4% to $11,000 as the company scaled back activities due to cash constraints.
• The company has a working capital deficit of $554,000 and a stockholders deficit of $693,000 as of June 30, 2026.
• A tender offer agreement was entered into on August 14, 2026, with European Guarantee Services S.r.l. to acquire all outstanding shares for a total purchase price of $35 million.
• The company's independent auditors have raised substantial doubt about its ability to continue as a going concern.
• The company's cash balance significantly decreased to $17,000 as of June 30, 2026, from $249,000 in the prior year.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative due to significant revenue decline, substantial net loss, and a going concern warning, despite a pending tender offer.

Positives

• A definitive tender offer agreement was signed on August 14, 2026, with European Guarantee Services S.r.l. to acquire all outstanding shares for $35 million, providing a potential exit for shareholders.
• The company received $880,000 in cash from Desmet in October 2024 for the assignment of certain patents related to vegetable oil refining, which provided capital for operations.
• The company retains a worldwide, exclusive, transferable, and royalty-free license to use the assigned patents in the fields of water and wastewater processing and alcoholic beverage enhancement.
• Xyra Corp., a wholly owned subsidiary, was incorporated in August 2025 to focus on crypto technologies, holding an exclusive license for the company's Cavitation Non-Thermal Plasma (CNTP) systems.

Negatives

• Revenue for fiscal year 2026 plummeted to $3,000, a 98.5% decrease from $203,000 in fiscal year 2025.
• Net loss for fiscal year 2026 was $1,404,000, a significant increase from $113,000 in the prior year.
• General and administrative expenses increased by 30.6% to $1,380,000, driven by stock-based compensation and consulting fees.
• Research and development expenses were reduced by 88.4% to $11,000 due to cash constraints.
• The company has a working capital deficit of $554,000 and a stockholders deficit of $693,000 as of June 30, 2026.
• The company's cash balance decreased to $17,000 as of June 30, 2026, from $249,000.
• The independent auditors have raised substantial doubt about the company's ability to continue as a going concern.
• The company's financial statements do not include any adjustments that might result from its inability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is in doubt due to recurring operating losses, a significant net loss in fiscal year 2026, and a substantial decrease in cash.
• The company may need to curtail operations if it fails to obtain additional debt or equity financing.
• The tender offer is subject to various conditions, including the acquisition of Alchemy Beverages Inc. shares and the tendering of at least 90% of Cavitation Technologies' shares.
• The company's financial performance is highly dependent on the successful development and commercialization of new technologies like Hydro-Plasma and Xyra Corp.'s crypto ventures.
• The company has a history of operating losses and has not generated significant revenue from its new ventures.
• The company's cash balance is critically low, posing a risk to its ability to fund ongoing operations and meet future contractual obligations.
• The tender offer is subject to regulatory review and approval, including CFIUS review, and may not be consummated.
• The company's financial statements do not include any adjustments that might result from the outcome of the going concern uncertainty.

Future Outlook

The company anticipates generating future revenues from its new technologies, including water treatment and remediation, agriculture water remediation, the Alchemy Beverages venture, Hydro-Plasma technology, and Xyra Corp.'s crypto technology initiatives. However, the company may require additional financing and there is no assurance of its availability or sufficiency. The tender offer for acquisition is pending regulatory review and shareholder tender thresholds.

Management Comments

• Management plans to generate revenues in future from the commercial applications of the new technologies discussed above.
• We may also attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital.
• Should management fail to obtain such financing, the Company may curtail its operations.
• Management concluded that as of June 30, 2026, our internal control over financial reporting was not effective, and that material weaknesses existed.

Industry Context

StockSavvy.ai notes that Cavitation Technologies operates in the specialized industrial processing and environmental technology sectors. The significant revenue decline and net loss highlight the challenges faced by companies in these capital-intensive and often long-development-cycle industries, especially those with limited operational history and ongoing R&D needs. The pending tender offer suggests a potential strategic shift or consolidation within this niche.

Comparison to Industry Standards

• The company's revenue of $3,000 for fiscal year 2026 is exceptionally low compared to industry standards for companies in the water treatment or industrial processing sectors, which typically generate millions in revenue.
• The net loss of $1,404,000, coupled with a significant increase in general and administrative expenses, indicates a higher burn rate relative to revenue than is typical for established players in the industry.
• The company's reliance on R&D and new technology development is common in this sector, but the drastic reduction in R&D spending due to cash constraints is a negative indicator compared to industry peers who often maintain consistent R&D investment.
• The going concern warning from auditors is a critical red flag, suggesting financial instability that is not standard for companies operating in the industrial technology space, especially those with patented technologies.

Corporate Governance

Legal Proceedings

• The company is not aware of any pending litigations that could have a material adverse effect on its business or financial condition.

Related Party Transactions

• As of June 30, 2026, $129,000 in accrued salary and payroll taxes were owed to a current shareholder and officer/director.
• In February 2025, the company settled accrued payroll and related taxes totaling $461,000 by issuing common stock ($90,000 fair value) and warrants ($100,000 fair value).

Stakeholder Impact

• Shareholders: The pending tender offer at $35 million provides a potential exit, but its consummation is subject to conditions. The significant financial distress raises concerns about the long-term value of their investment.
• Creditors: The company's going concern status and low cash balance may impact its ability to meet its debt obligations.
• Employees: The company has only two full-time employees and relies on consultants. Financial instability could affect employment security.
• Suppliers: The company has no long-term contracts with suppliers, and its financial condition could impact its ability to pay for goods and services.

Next Steps

• The tender offer by European Guarantee Services S.r.l. is subject to regulatory review and satisfaction of certain conditions, including shareholder tender thresholds.
• The company plans to continue developing its new technologies, including Hydro-Plasma and Xyra Corp.'s crypto ventures.
• Management will seek additional debt and/or equity financing to fund operations and working capital.
• The company will continue to pursue additional customers for its water treatment solutions, primarily in the Permian Basin.
• Alchemy Beverages, Inc. is expected to complete its financial audit in Q1 fiscal 2027 and is pursuing commercial production of Barmuze.

Key Dates

Recommendation

The filing presents a dire financial situation with a severe revenue drop, a substantial net loss, a critical going concern warning, and very low cash reserves. While a tender offer is pending, its completion is uncertain and subject to significant conditions. The company's ability to execute its future plans is highly dependent on securing additional financing, which is not guaranteed. Given these factors, the risk profile is extremely high, suggesting a sell recommendation.

Keywords

Cavitation Technologies, Form 10-K, Annual Report, Tender Offer, Going Concern, Revenue Decline, Net Loss, Hydro-Plasma